Research
Hormonal
Obesity and metabolic syndrome significantly increase the risk of hepatocellular carcinoma (HCC), with risk escalating as BMI increases and being further amplified by the presence of type 2 diabetes.
Maintaining a healthy body weight is a critical strategy for reducing the risk of liver cancer. The risk of developing hepatocellular carcinoma increases significantly with higher BMI, and this risk is even higher if you have type 2 diabetes. Focus on metabolic health through diet and lifestyle changes to lower this risk.
StrongSupportsHIGH confidence
a recent meta-analysis including more than seven million participants concluded that the summary RR of liver cancer was 17% for overweight subjects and 89% for the obese, with an average 24% increase in risk for each 5 kg/m2 increase in BMI
Why this rating
Based on large-scale epidemiological studies and meta-analyses involving millions of participants.
Source
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Andrea Marengo et al. · Annual Review of Medicine · 2015
DOI 10.1146/annurev-med-090514-013832
narrative_reviewCited 790×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Hepatocellular carcinoma can develop in patients with nonalcoholic fatty liver disease (NAFLD) even in the absence of cirrhosis, often presenting with larger tumors and poorer prognosis due to lack of surveillance.Good
- Metformin use is associated with a reduced incidence of hepatocellular carcinoma in patients with type 2 diabetes, whereas sulfonylurea or insulin use may increase risk.Good
- Statin use is associated with a reduced incidence of hepatocellular carcinoma in patients with NAFLD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →